Evidence map›Paper›PMID 28494029›Full record

ArticlePLoS pathogens2017

Characterization of miR-122-independent propagation of HCV.

Chikako Ono, Takasuke Fukuhara, Daisuke Motooka, Shota Nakamura, Daisuke Okuzaki, Satomi Yamamoto, Tomokazu Tamura, Hiroyuki Mori, Asuka Sato, Kentaro Uemura and 12 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Identification of claudin-3 as an entry factor for rat hepacivirus.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. miR-122-based therapies select for three distinct resistance mechanisms based on alterations in RNA structure.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Chikako OnoDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Takasuke FukuharaDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Daisuke MotookaDepartment of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Shota NakamuraDepartment of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Daisuke OkuzakiDNA-Chip Developmental Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.ORCID http://orcid.org/0000-0002-4552-783X
Satomi YamamotoDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Tomokazu TamuraDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.ORCID http://orcid.org/0000-0003-1395-6610
Hiroyuki MoriDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Asuka SatoDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Kentaro UemuraDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Yuzy FauzyahDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Takeshi KuriharaDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.ORCID http://orcid.org/0000-0002-3063-9126
Takahiro SudaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Akira NishioDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Su Su HmweDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Toru OkamotoDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Tomohide TatsumiDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Tetsuo TakeharaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Kazuaki ChayamaDepartment of Medicine and Molecular Science, Hiroshima University School of Medicine, Hiroshima, Japan.
Takaji WakitaDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Kazuhiko KoikeDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yoshiharu MatsuuraDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.ORCID http://orcid.org/0000-0001-9091-8285
The University of Osaka · JPNational Institute of Infectious Diseases · JPHiroshima University · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

miR-122, a liver-specific microRNA, is one of the determinants for liver tropism of hepatitis C virus (HCV) infection. Although miR-122 is required for efficient propagation of HCV, we have previously shown that HCV replicates at a low rate in miR-122-deficient cells, suggesting that HCV-RNA is capable of propagating in an miR-122-independent manner. We herein investigated the roles of miR-122 in both the replication of HCV-RNA and the production of infectious particles by using miR-122-knockout Huh7 (Huh7-122KO) cells. A slight increase of intracellular HCV-RNA levels and infectious titers in the culture supernatants was observed in Huh7-122KO cells upon infection with HCV. Moreover, after serial passages of HCV in miR-122-knockout Huh7.5.1 cells, we obtained an adaptive mutant, HCV122KO, possessing G28A substitution in the 5'UTR of the HCV genotype 2a JFH1 genome, and this mutant may help to enhance replication complex formation, a possibility supported by polysome analysis. We also found the introduction of adaptive mutation around miR-122 binding site in the genotype 1b/2a chimeric virus, which originally had an adenine at the nucleotide position 29. HCV122KO exhibited efficient RNA replication in miR-122-knockout cells and non-hepatic cells without exogenous expression of miR-122. Competition assay revealed that the G28A mutant was dominant in the absence of miR-122, but its effects were equivalent to those of the wild type in the presence of miR-122, suggesting that the G28A mutation does not confer an advantage for propagation in miR-122-rich hepatocytes. These observations may explain the clinical finding that the positive rate of G28A mutation was higher in miR-122-deficient PBMCs than in the patient serum, which mainly included the hepatocyte-derived virus from HCV-genotype-2a patients. These results suggest that the emergence of HCV mutants that can propagate in non-hepatic cells in an miR-122-independent manner may participate in the induction of extrahepatic manifestations in chronic hepatitis C patients.

Indexed as

Virus Replication5' Untranslated RegionsCell Line, TumorHepacivirusHepatitis CHepatocytesHumansLiverMicroRNAsMutationOrgan SpecificityRNA, Viral5' Untranslated RegionsMicroRNAsMIRN122 microRNA, humanRNA, Viral

Identifiers

PMID28494029
PMCPMC5441651
OpenAlexW2611964938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.